Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 130

1.

A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients.

Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen M, Lehti K, Hautaniemi S, Vähärautio A, Grénman S, Carpén O, Kauppi L.

Clin Cancer Res. 2018 Jun 1. pii: clincanres.3770.2017. doi: 10.1158/1078-0432.CCR-17-3770. [Epub ahead of print]

PMID:
29858219
2.

Mathematical modeling predicts response to chemotherapy and drug combinations in ovarian cancer.

Kozłowska E, Färkkilä A, Vallius T, Carpén O, Kemppainen J, Grénman S, Lehtonen R, Hynninen J, Hietanen S, Hautaniemi S.

Cancer Res. 2018 May 16. pii: canres.3746.2017. doi: 10.1158/0008-5472.CAN-17-3746. [Epub ahead of print]

PMID:
29769198
3.

Clinical Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Response Evaluation after Primary Treatment of Advanced Epithelial Ovarian Cancer.

Hynninen J, Laasik M, Vallius T, Kemppainen J, Grönroos S, Virtanen J, Casado J, Hautaniemi S, Grenman S, Seppänen M, Auranen A.

Clin Oncol (R Coll Radiol). 2018 May 9. pii: S0936-6555(18)30236-X. doi: 10.1016/j.clon.2018.04.007. [Epub ahead of print]

PMID:
29753662
4.

Lymphatic endothelium stimulates melanoma metastasis and invasion via MMP14-dependent Notch3 and β1-integrin activation.

Pekkonen P, Alve S, Balistreri G, Gramolelli S, Tatti-Bugaeva O, Paatero I, Niiranen O, Tuohinto K, Perälä N, Taiwo A, Zinovkina N, Repo P, Icay K, Ivaska J, Saharinen P, Hautaniemi S, Lehti K, Ojala PM.

Elife. 2018 May 1;7. pii: e32490. doi: 10.7554/eLife.32490.

5.

Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes.

Ullah I, Karthik GM, Alkodsi A, Kjällquist U, Stålhammar G, Lövrot J, Martinez NF, Lagergren J, Hautaniemi S, Hartman J, Bergh J.

J Clin Invest. 2018 Apr 2;128(4):1355-1370. doi: 10.1172/JCI96149. Epub 2018 Feb 26.

6.

Let-7 microRNA controls invasion-promoting lysosomal changes via the oncogenic transcription factor myeloid zinc finger-1.

Tvingsholm SA, Hansen MB, Clemmensen KKB, Brix DM, Rafn B, Frankel LB, Louhimo R, Moreira J, Hautaniemi S, Gromova I, Jäättelä M, Kallunki T.

Oncogenesis. 2018 Feb 3;7(2):14. doi: 10.1038/s41389-017-0014-6.

7.

MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma.

Leivonen SK, Icay K, Jäntti K, Siren I, Liu C, Alkodsi A, Cervera A, Ludvigsen M, Hamilton-Dutoit SJ, d'Amore F, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S.

Blood Cancer J. 2017 Dec 15;7(12):654. doi: 10.1038/s41408-017-0033-8.

8.

Dynamic visualization of multi-level molecular data: The Director package in R.

Icay K, Liu C, Hautaniemi S.

Comput Methods Programs Biomed. 2018 Jan;153:129-136. doi: 10.1016/j.cmpb.2017.10.013. Epub 2017 Oct 12.

PMID:
29157446
9.

Alternative splicing discriminates molecular subtypes and has prognostic impact in diffuse large B-cell lymphoma.

Leivonen SK, Taskinen M, Cervera A, Karjalainen-Lindsberg ML, Delabie J, Holte H, Lehtonen R, Hautaniemi S, Leppä S.

Blood Cancer J. 2017 Aug 25;7(8):e596. doi: 10.1038/bcj.2017.71.

10.

Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei.

Saarinen L, Nummela P, Thiel A, Lehtonen R, Järvinen P, Järvinen H, Aaltonen LA, Lepistö A, Hautaniemi S, Ristimäki A.

PLoS One. 2017 Apr 20;12(4):e0174898. doi: 10.1371/journal.pone.0174898. eCollection 2017.

11.

PerPAS: Topology-Based Single Sample Pathway Analysis Method.

Liu C, Lehtonen R, Hautaniemi S.

IEEE/ACM Trans Comput Biol Bioinform. 2018 May-Jun;15(3):1022-1027. doi: 10.1109/TCBB.2017.2679745. Epub 2017 Mar 8.

PMID:
28287981
12.

Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma.

Meriranta L, Pasanen A, Louhimo R, Cervera A, Alkodsi A, Autio M, Taskinen M, Rantanen V, Karjalainen-Lindsberg ML, Holte H, Delabie J, Lehtonen R, Hautaniemi S, Leppä S.

Haematologica. 2017 May;102(5):e195-e198. doi: 10.3324/haematol.2016.157495. Epub 2017 Feb 9. No abstract available.

13.

DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival.

Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN.

Oncotarget. 2017 Jan 3;8(1):1074-1082. doi: 10.18632/oncotarget.13718.

14.

Language-Agnostic Reproducible Data Analysis Using Literate Programming.

Vassilev B, Louhimo R, Ikonen E, Hautaniemi S.

PLoS One. 2016 Oct 6;11(10):e0164023. doi: 10.1371/journal.pone.0164023. eCollection 2016.

15.

Complete androgen insensitivity syndrome caused by a deep intronic pseudoexon-activating mutation in the androgen receptor gene.

Känsäkoski J, Jääskeläinen J, Jääskeläinen T, Tommiska J, Saarinen L, Lehtonen R, Hautaniemi S, Frilander MJ, Palvimo JJ, Toppari J, Raivio T.

Sci Rep. 2016 Sep 9;6:32819. doi: 10.1038/srep32819.

16.

Data integration to prioritize drugs using genomics and curated data.

Louhimo R, Laakso M, Belitskin D, Klefström J, Lehtonen R, Hautaniemi S.

BioData Min. 2016 May 26;9:21. doi: 10.1186/s13040-016-0097-1. eCollection 2016.

17.

SePIA: RNA and small RNA sequence processing, integration, and analysis.

Icay K, Chen P, Cervera A, Rantanen V, Lehtonen R, Hautaniemi S.

BioData Min. 2016 May 20;9:20. doi: 10.1186/s13040-016-0099-z. eCollection 2016.

18.

Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.

Tambe M, Pruikkonen S, Mäki-Jouppila J, Chen P, Elgaaen BV, Straume AH, Huhtinen K, Cárpen O, Lønning PE, Davidson B, Hautaniemi S, Kallio MJ.

Oncotarget. 2016 Mar 15;7(11):12267-85. doi: 10.18632/oncotarget.7860.

19.

Oncogenic Herpesvirus Utilizes Stress-Induced Cell Cycle Checkpoints for Efficient Lytic Replication.

Balistreri G, Viiliäinen J, Turunen M, Diaz R, Lyly L, Pekkonen P, Rantala J, Ojala K, Sarek G, Teesalu M, Denisova O, Peltonen K, Julkunen I, Varjosalo M, Kainov D, Kallioniemi O, Laiho M, Taipale J, Hautaniemi S, Ojala PM.

PLoS Pathog. 2016 Feb 18;12(2):e1005424. doi: 10.1371/journal.ppat.1005424. eCollection 2016 Feb.

20.

Transmembrane prostatic acid phosphatase (TMPAP) delays cells in G1 phase of the cell cycle.

Araujo CL, Quintero IB, Ovaska K, Herrala AM, Hautaniemi S, Vihko PT.

Prostate. 2016 Feb;76(2):151-62. doi: 10.1002/pros.23105. Epub 2015 Sep 30.

PMID:
26419820

Supplemental Content

Loading ...
Support Center